Oracle has introduced an oncology EHR, reportedly offering access to built-in AI agents and clinical decision support, intended to connect results, decision making, and action across the cancer care pathway.
Oracle Health Oncology EHR is said to incorporate oncology-specific workflows, AI-powered clinical intelligence, and connected information to support patient care from diagnosis through to treatment and follow-up, the company shares.
The company highlights the functionality of its AI assistant for oncologists, stating: “From patient snapshots and pre-visit summaries that surface what has changed, to specialised assistants for Tumor Board preparation and guideline-grounded treatment planning, the assistant can help clinicians make sense of complex information and carry their decisions into workflows such as orders, referrals, documentation, and coding.”
Other capabilities on offer are said to include a chronological view of cancer-related diagnoses and treatments; connected worklists for nurse navigators; intelligent precision oncology insights unifying genomic, radiology, pathology, laboratory, pharmacy, and social determinants of health data to support treatment decisions; and regimen planning workflows supporting chemotherapy and immunotherapy ordering with lifetime cumulative-dose calculations.
Wider trend: The role of digital in cancer care
An NHS cancer innovation programme is set to accept applications in October, with the aim to improve productivity, support managing demand or capacity in cancer care pathways, and to support earlier detection and diagnosis of cancer through screening or diagnostic tools. Two funding models are offered to support varying stages of innovation maturity and overcome barriers to adoption, with the first offering up to £3 million over a maximum of 24 months for single UK or EU organisations with “demonstrable partnerships” with NHS organisations in England and an independent evaluation partner. “Additional engagement with Cancer Alliances and/or Health Innovation Networks is strongly encouraged,” it states.
AI enabled breast cancer screening is reportedly helping patients at Harrogate and District NHS Foundation Trust (HDFT), thanks to the introduction of a new scanner funded by £40,000 from the Harrogate Hospital & Community Charity. The AI enabled HER2 tissue scanning system works by capturing high resolution digital images of breast cancer tissue samples, using an AI algorithm to help pathologists assess HER2 status by detecting the presence of the HER2/neu gene that can be a cause of breast cancer, the trust shares.
A partnership has been launched between the DATA-CAN data research hub for cancer hosted at Leeds Teaching Hospitals and the West Midlands Secure Data Environment to support access to high quality cancer data for researchers. The partnership draws on pseudonymised patient data from patient records at major cancer centres across the UK, including on diagnosis, treatments, test results, and patient outcomes. The first dataset has been uploaded to the WM SDE, with three further datasets currently in development, Leeds Teaching shares.
